Pear Therapeutics Debt to Equity

The latest debt-to-equity ratio for PEAR is 1.24. That is above the sector sector average of 0.2. Investors often review this figure alongside Pear Therapeutics's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, PEAR currently prints 1.24 for debt-to-equity ratio, while the sector average sits near 0.2. That is roughly 518.5% above the sector mean. Large gaps often invite a closer look at Pear Therapeutics's growth, margins, and balance sheet.

A debt-to-equity ratio of 1.24 for Pear Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (0.2) and with PEAR's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting PEAR's debt-to-equity ratio (1.24), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.